BioSpace News Archive

Invivyd, Inc. announced that VYD222, a half-life extended investigational monoclonal antibody, shows continued in vitro neutralization activity in pseudovirus assays designed to represent the predominant emerging variants of SARS-CoV-2, including the KP.1.1 FLiRT and KP.3 variants.

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of T cell receptor -engineered T cell therapies for the treatment of patients with cancer, announced changes to its Board of Directors.

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation, shared new clinical data from its ongoing KT-333 Phase 1 trial.

Syndax Pharmaceuticals, a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced updated data from multiple combination trials of revumenib, the Company’s potent, selective, small molecule menin inhibitor, in patients with acute leukemias.

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, announced that it entered into separate, privately negotiated exchange agreements with certain holders of its 2.75% Convertible Senior Notes due 2027.

Aptose Biosciences Inc. announced a clinical poster presentation and a preclinical e-poster at the European Hematology Association 2024 Hybrid Congress in Madrid, Spain.

Intellia Therapeutics, Inc., a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, announced the appointment of Brian Goff to its board of directors.

Disc Medicine, Inc. announced positive additional data for bitopertin in erythropoietic protoporphyria, including additional analyses of AURORA data that further demonstrated the clinical activity of bitopertin and highlighted meaningful improvements in light tolerance, phototoxic reactions, and quality of life.

Wugen, Inc. announces positive Phase 2 results for the company’s investigational anti-CD7 CAR-T therapy, WU-CART-007, in patients with relapsed/refractory t-cell acute lymphoblastic leukemia/lymphoma.

Cogent Biosciences, Inc. announced additional data from Part 1 of its ongoing SUMMIT clinical trial evaluating the selective KIT D816V inhibitor, bezuclastinib, in patients with nonadvanced systemic mastocytosis.